Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer from poor translation to the clinic. To serve as a more physiological preclinical model for immunotherapy studies, this protocol has been developed to evaluate the treatment of human tumors in a mouse reconstituted with a human immune system. This unique protocol demonstrates the development of human immune system (HIS, "humanized") mice, followed by implantation of a human tumor, either a cell-line derived xenograft (CDX) or a patient derived xenograft (PDX). HIS mice are generated by injecting CD34+ human hematopoietic stem cells isolated from umbilical cord blood into neonatal BRGS (BALB/c Rag2-/- IL2RγC-/- NODSIRPα) highly immunodeficient mice that are also capable of accepting a xenogeneic tumor. The importance of the kinetics and characteristics of the human immune system development and tumor implantation is emphasized. Finally, an in-depth evaluation of the tumor microenvironment using flow cytometry is described. In numerous studies using this protocol, it was found that the tumor microenvironment of individual tumors is recapitulated in HIS-PDX mice; "hot" tumors exhibit large immune infiltration while "cold" tumors do not. This model serves as a testing ground for combination immunotherapies for a wide range of human tumors and represents an important tool in the quest for personalized medicine.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Journal of visualized experiments : JoVE - (2022), 190 vom: 16. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lanis, Jordi M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 03.01.2023 Date Revised 22.10.2023 published: Electronic ErratumIn: J Vis Exp. 2023 May 25;(195):. - PMID 37227773 Citation Status MEDLINE |
|---|
| doi: |
10.3791/64606 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351033041 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351033041 | ||
| 003 | DE-627 | ||
| 005 | 20231226050345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3791/64606 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351033041 | ||
| 035 | |a (NLM)36591990 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lanis, Jordi M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2023 | ||
| 500 | |a Date Revised 22.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: J Vis Exp. 2023 May 25;(195):. - PMID 37227773 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer from poor translation to the clinic. To serve as a more physiological preclinical model for immunotherapy studies, this protocol has been developed to evaluate the treatment of human tumors in a mouse reconstituted with a human immune system. This unique protocol demonstrates the development of human immune system (HIS, "humanized") mice, followed by implantation of a human tumor, either a cell-line derived xenograft (CDX) or a patient derived xenograft (PDX). HIS mice are generated by injecting CD34+ human hematopoietic stem cells isolated from umbilical cord blood into neonatal BRGS (BALB/c Rag2-/- IL2RγC-/- NODSIRPα) highly immunodeficient mice that are also capable of accepting a xenogeneic tumor. The importance of the kinetics and characteristics of the human immune system development and tumor implantation is emphasized. Finally, an in-depth evaluation of the tumor microenvironment using flow cytometry is described. In numerous studies using this protocol, it was found that the tumor microenvironment of individual tumors is recapitulated in HIS-PDX mice; "hot" tumors exhibit large immune infiltration while "cold" tumors do not. This model serves as a testing ground for combination immunotherapies for a wide range of human tumors and represents an important tool in the quest for personalized medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Video-Audio Media | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 700 | 1 | |a Lewis, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Strassburger, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Bagby, Stacey M |e verfasserin |4 aut | |
| 700 | 1 | |a Dominguez, Adrian T A |e verfasserin |4 aut | |
| 700 | 1 | |a Marín-Jiménez, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Pelanda, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Pitts, Todd M |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Julie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of visualized experiments : JoVE |d 2006 |g (2022), 190 vom: 16. Dez. |w (DE-627)NLM181595761 |x 1940-087X |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g number:190 |g day:16 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3791/64606 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |e 190 |b 16 |c 12 | ||